Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

F-STAR THERAPEUTICS, INC.

(FSTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/10/2021 05/11/2021 05/12/2021 05/13/2021 05/14/2021 Date
6.66(c) 6.81(c) 6.64(c) 6.62(c) 6.57(c) Last
463 755 162 021 294 530 413 599 148 222 Volume
-6.59% +2.25% -2.50% -0.30% -0.76% Change
More quotes
Financials (USD)
Sales 2021 4,25 M - -
Net income 2021 -41,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,67x
Yield 2021 -
Sales 2022 4,06 M - -
Net income 2022 -47,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,18x
Yield 2022 -
Capitalization 121 M 121 M -
Capi. / Sales 2021 28,4x
Capi. / Sales 2022 29,7x
Nbr of Employees 77
Free-Float 45,7%
More Financials
Company
F-Star Therapeutics, Inc., formerly Spring Bank Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics for the treatment of viral infections, inflammatory diseases and cancers using its small molecule nucleotide platform. The Company is developing its product inarigivir soproxil (inarigivir), for the treatment of... 
More about the company
Notations Surperformance© of F-star Therapeutics, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about F-STAR THERAPEUTICS, INC.
05/12F STAR THERAPEUTICS  : Announces Proposed Public Offering of Common Stock (Form ..
PU
05/10F STAR THERAPEUTICS  : to Announce First Quarter Results and Corporate Update Ca..
AQ
05/10F-STAR THERAPEUTICS, INC.  : Entry into a Material Definitive Agreement, Other E..
AQ
05/07F STAR THERAPEUTICS  : Falls Sharply After Pricing $65 Million Common Stock Offe..
MT
05/07Wall Street Rises Midday, Treasuries Edge Up After Slower Job Growth Data
MT
05/07MIDDAY REPORT : Wall Street Rises Midday, Treasuries Edge Up After Slower Job Gr..
MT
05/07Wall Street Mixed Pre-Bell After Nonfarm Payrolls Report
MT
05/07F STAR THERAPEUTICS  : Announces Pricing of $65 Million Public Offering of Commo..
AQ
05/07F STAR THERAPEUTICS  : Proposes Common Stock Offering
MT
05/06F-star Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
GL
05/06F-STAR THERAPEUTICS, INC.  : Termination of a Material Definitive Agreement (for..
AQ
04/19Study Published in Nature Shows F-Star's STING Agonist SB 11285 Enhances Prec..
GL
04/16F STAR THERAPEUTICS  : Oppenheimer Initiates F-star Therapeutics at Outperform R..
MT
04/14F-STAR THERAPEUTICS, INC.  : Other Events, Financial Statements and Exhibits (fo..
AQ
04/10F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster
GL
More news
News in other languages on F-STAR THERAPEUTICS, INC.
04/01F-STAR THERAPEUTICS  : Merck KGaA übt Option für mehr Kooperation aus
More news
Analyst Recommendations on F-STAR THERAPEUTICS, INC.
More recommendations
Chart F-STAR THERAPEUTICS, INC.
Duration : Period :
F-star Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends F-STAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 30,52 $
Last Close Price 6,57 $
Spread / Highest target 433%
Spread / Average Target 364%
Spread / Lowest Target 311%
EPS Revisions
Managers and Directors
NameTitle
Eliot Richard Forster President, Chief Executive Officer & Director
Darlene M. Deptula-Hicks Chief Financial Officer & Treasurer
Nessan Bermingham Chairman
Neil Brewis Chief Scientific Officer
Louis Kayitalire Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
F-STAR THERAPEUTICS, INC.-33.43%121
GILEAD SCIENCES, INC.18.28%85 949
WUXI APPTEC CO., LTD.13.72%57 931
VERTEX PHARMACEUTICALS-8.15%56 197
REGENERON PHARMACEUTICALS7.05%53 499
BIONTECH SE136.47%46 558